alpha2A-adrenergic receptors in the genetics, pathogenesis, and treatment of type 2 diabetes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20371458.
- Also identified by DOI 10.1126/scitranslmed.3000606.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Insulin secretion from pancreatic islets is inhibited by the activation of beta cell alpha(2A)-adrenergic receptors (alpha(2A)ARs). Increased expression of alpha(2A)ARs, then, would depress insulin release, which is a pathogenic mechanism of type 2 diabetes. Using congenic rats derived from an inbred model of type 2 diabetes, Rosengren et al. showed that a chromosomal region that includes the gene encoding alpha(2A)AR, Adra2a, is associated with increased messenger RNA and protein expression and decreased insulin release. A single-nucleotide polymorphism in the human ADRA2A gene was associated with decreased insulin secretion in normal people during glucose challenge and was also associated with type 2 diabetes. These findings offer another genetic association locus for the disease, with concordant biochemical and expression phenotypes, and also provide a potential new pathway for therapeutic intervention.
Medical subject headings
- Diabetes Mellitus, Type 2
- Receptors, Adrenergic, alpha-2